SciBX on Science, Targets & Mechanisms
Taken to heart
By Tracey Baas, Senior Editor
Published on Thursday, December 1, 2011
A Stanford study has suggested that the mitochondrial enzyme ALDH2 activator Alda-1 could decrease the risk of cardiac injury in patients treated with nitroglycerin. ALDEA Pharmaceuticals has already raised money to optimize Alda-1 for clinical use, while other Aldas are under development.
To read this article, you must be a SciBX subscriber through BioCentury. If you have subscribed to SciBX through our partner, Nature Publishing Group, please go to http://www.nature.com/scibx. Otherwise, please click below to contact us or start a free trial.
All contents Copyright © 1993-2012 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement and the BioCentury Terms of Use. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions at www.biocentury.com. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
|
Purchase This Article
Learn what you're missing.
Purchase Reprints
Redistribute, reproduce or forward this article.
SciBX: Science-Business eXchange
BioCentury's weekly translational science journal, published in collaboration with Nature Publishing Group:
- Selects from hundreds of scientific papers published each week to identify early opportunities for investment, alliances and partnerships
- Reports on the most commercially relevant developments
Thank You
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your records.
close [ X ]